You are here

Abbreviated NDA For Valproate Sodium Injection Approved

SCHAUMBURG, Ill., June 30 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of valproate sodium injection. Valproate sodium injection, the generic equivalent of Abbott Laboratories' Depacon® Sodium Injection, is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures.

"Valproate represents the fifth product approval APP has received thus far in 2003 and complements our growing critical care offering," said Patrick Soon-Shiong, M.D., chairman, president and chief executive officer. "APP has launched three products this year. We also have received tentative approvals for carboplatin and fluconazole, both of which are large market opportunity drugs with combined innovator sales exceeding $700 million in 2002, according to IMS, and whose patents expire in 2004."

Valproate sodium injection is an intravenous alternative in patients for whom oral administration of valproate products is not feasible. Valproate products have a "black box" warning for patients with hepatic disease or significant hepatic dysfunction.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs